Overview of the year 2023 at Pharmacogenomics

PharmacogenomicsVol. 25, No. 1 ForewordOverview of the year 2023 at PharmacogenomicsSarah JonesSarah Jones*Author for correspondence: E-mail Address: s.jones@futuremedicine.comFuture Medicine Ltd, Unitec House, 2 Albert Place, London, N3 1QB, UKPublished Online:19 Dec 2023https://doi.org/10.2217/pgs-2023-0228AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: ABCG2CYP2D6HLA-B*38:02personalized medicinepharmacogenomicsrosuvastatinReferences1. Devanathan R, Alladi CG, Ravichandran M, Ramasamy K, Uppugunduri CR. Impact of pharmacogenomics in achieving personalized/precision medicine in the clinical setting: a symposium report. Pharmacogenomics 24(3), 123–129 (2023).CASGoogle Scholar2. Bollinger A, Jeiziner C, Meyer zu Schwabedissen HE et al. Severe systemic adverse reactions to ophthalmic timolol in a CYP2D6 homozygous *4 allele carrier: a case report. Pharmacogenomics 24(14), 739–746 (2023).CASGoogle Scholar3. Wang F, Li W, Wang X, Luo X, Dai P. A single-tube multiplex real-time PCR for HLA-B*38:02 genotype by detecting highly specific SNPs. Pharmacogenomics 24(1), 5–14 (2023).CASGoogle Scholar4. Alrajeh K, Roman YM. The frequency of rs2231142 in ABCG2 among Asian subgroups: implications for personalized rosuvastatin dosing. Pharmacogenomics 24(1), 15–26 (2023).CASGoogle Scholar5. Cramer EY, Bartlet J, Chan ER et al. Pharmacogenomic variation in the Malagasy population: implications for the antimalarial drug primaquine metabolism. Pharmacogenomics 24(11), 583–597 (2023).CASGoogle Scholar6. AlAzzeh O, Roman YM. The frequency of rs2231142 in ABCG2 among Native Hawaiian and Pacific Islander subgroups: implications for personalized rosuvastatin dosing. Pharmacogenomics 24(3), 173–182 (2023).CASGoogle Scholar7. Behr MP, Gammal RS, Matthews ML, Wang VC. Healthcare professionals' knowledge, confidence and perceptions of pharmacogenomics in primary care and pain management. Pharmacogenomics 24(7), 371–379 (2023).CASGoogle Scholar8. Mapira NL, Thelingwani RS, Chikwambi Z, Kuona P, Masimirembwa C. Pharmacogenetics of pain management in Zimbabwean patients with sickle cell disease. Pharmacogenomics 24(7), 359–369 (2023).CASGoogle Scholar9. Cacabelos R, Carril JC, Corzo L et al. Pharmacogenetics of anxiety and depression in Alzheimer's disease. Pharmacogenomics 24(1), 27–57 (2023).CASGoogle Scholar10. Alsultan A, Alalwan AA, Alshehri B. Interethnic differences in drug response: projected impact of genetic variations in the Saudi population. Pharmacogenomics 24(12), 685–696 (2023).CASGoogle ScholarFiguresReferencesRelatedDetails Vol. 25, No. 1 STAY CONNECTED Metrics Downloaded 48 times History Received 7 December 2023 Accepted 7 December 2023 Published online 19 December 2023 Published in print January 2024 Information© 2023 Future Medicine LtdKeywordsABCG2CYP2D6HLA-B*38:02personalized medicinepharmacogenomicsrosuvastatinFinancial disclosureS Jones is an employee of Future Medicine Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Competing interests disclosureThe authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Writing disclosureNo writing assistance was utilized in the production of this manuscript.PDF download